首頁 > 市場調查報告書 > 製藥

呼吸器

全球肺病治療市場研究報告 - 2023 年至 2030 年行業分析、規模、佔有率、成長、趨勢和預測

市場調查報告書

商品編碼

1346841

全球肺病治療市場研究報告 - 2023 年至 2030 年行業分析、規模、佔有率、成長、趨勢和預測

Global Lung Disease Therapeutics Market Research Report - Industry Analysis, Size, Share, Growth, Trends and Forecast 2023 to 2030

出版日期: 2023年08月01日 | 出版商:

Value Market Research | 英文 242 Pages | 商品交期: 最快1-2個工作天內

價格

簡介目錄圖表

全球肺病治療市場需求預計將從 2022 年的 804.1 億美元增至 2030 年的近 1164.1 億美元，2023-2030 年研究期間年複合成長率為 4.7%。

肺部疾病治療是指旨在管理和治療各種肺部相關病症和疾病的醫學治療和干涉措施。它涵蓋影響呼吸系統的疾病，包括影響肺功能和整體呼吸系統健康的急性和慢性疾病。這些療法可能涉及多種方法，包括藥物、療法、生活方式的改變，在某些情況下還包括手術干涉。

市場動態：

在污染和人口老齡化等因素的推動下，肺部疾病的患病率不斷上升，刺激了對有效治療方法的需求。環境因素、技術進步和研究導致對治療的需求不斷成長。個性化醫療和新興生物製藥（例如標靶治療）增強了治療選擇。不斷成長的醫療保健支出、早期診斷意識和更嚴格的監管標準發揮了重要作用。 COVID-19 大流行凸顯了呼吸系統健康的重要性並加速了該領域的研究。全球舉措、醫療保健基礎設施發展和以患者為中心的方法進一步影響著市場。隨著患者和醫療保健專業人員尋求改進的治療方法，市場預計將不斷發展。

該研究報告涵蓋波特五力模型、市場吸引力分析和價值鏈分析。這些工具有助於清晰地了解行業結構並評估全球範圍內的競爭吸引力。此外，這些工具還對全球肺病治療市場的每個細分市場進行了包容性評估。肺部疾病治療行業的成長和趨勢為這項研究提供了整體方法。

區域分析：

本節涵蓋區域前景，重點介紹北美、歐洲、亞太地區、拉丁美洲以及中東和非洲肺病治療市場當前和未來的需求。此外，該報告重點關注所有主要地區各個應用領域的需求、估計和預測。

該研究報告還涵蓋了市場主要參與者的全面概況以及對全球競爭格局的深入了解。肺病治療市場的主要參與者包括葛蘭素史克、阿斯利康、勃林格殷格翰、諾華、邁蘭、Vertex Pharmaceuticals、F.Hoffam La Roche、Teva Pharmaceuticals、Cipla、Fibrogen、Liminal Biosciences、PharmAkea Therapeutics、IQVIA 。本節包含競爭格局的整體視圖，包括各種戰略發展，例如關鍵併購、未來產能、合作夥伴關係、財務概況、合作、新產品開發、新產品發布和其他發展。

如果您有任何客製化要求，請寫信給我們。我們的研究團隊可以根據您的需求提供客製化報告。

區域展望
介紹
北美銷售分析
- 概覽、歷史和預測數據銷售分析
- 北美按細分市場銷售分析
- 北美按國家/地區銷售分析
- 美國銷售分析
- 加拿大銷售分析
- 墨西哥銷售分析
歐洲銷售分析
- 概覽、歷史和預測數據銷售分析
- 歐洲按細分市場銷售分析
- 歐洲按國家/地區銷售分析
- 英國銷售分析
- 法國銷售分析
- 德國銷售分析
- 義大利銷售分析
- 俄羅斯銷售分析
- 歐洲其他地區銷售分析
亞太地區銷售分析
- 概覽、歷史和預測數據銷售分析
- 亞太地區按細分市場銷售分析
- 亞太地區國家/地區銷售分析
- 中國銷售分析
- 印度銷售分析
- 日本銷售分析
- 韓國銷售分析
- 澳大利亞銷售分析
- 東南亞銷售分析
- 亞太地區其他地區銷售分析
拉丁美洲銷售分析
- 概覽、歷史和預測數據銷售分析
- 拉丁美洲按細分市場銷售分析
- 拉丁美洲按國家/地區銷售分析
- 巴西銷售分析
- 阿根廷銷售分析
- 秘魯銷售分析
- 智利銷售分析
- 拉丁美洲其他地區銷售分析
中東和非洲銷售分析
- 概覽、歷史和預測數據銷售分析
- 中東和非洲按細分市場銷售分析
- 中東和非洲國家銷售分析
- 沙烏地阿拉伯銷售分析
- 阿拉伯聯合大公國銷售分析
- 以色列銷售分析
- 南非銷售分析
- 中東其他地區和非洲銷售分析

第 9 章：肺病治療公司的競爭格局

肺病治療市場競爭
夥伴關係/協作/協議
併購
新產品發布
其他發展

第 10 章：公司簡介

公司股份分析
市場集中度
GSK

公司簡介
公司收入
產品
最近的發展

AstraZeneca

公司簡介
公司收入
產品
最近的發展

Boehringer Ingelheim

公司簡介
公司收入
產品
最近的發展

Novartis

公司簡介
公司收入
產品
最近的發展

Mylan

公司簡介
公司收入
產品
最近的發展

Vertex Pharmaceuticals

公司簡介
公司收入
產品
最近的發展

F.Hoffam La Roche

公司簡介
公司收入
產品
最近的發展

Teva Pharmaceuticals

公司簡介
公司收入
產品
最近的發展

Cipla

公司簡介
公司收入
產品
最近的發展

Fibrogen

公司簡介
公司收入
產品
最近的發展

Liminal Biosciences

公司簡介
公司收入
產品
最近的發展

PharmAkea Therapeutics

公司簡介
公司收入
產品
最近的發展

IQVIA

公司簡介
公司收入
產品
最近的發展

注意 - 在公司概況中，財務詳細資訊和近期發展視情況而定，或者如果是私營公司，則可能不包括在內

簡介目錄圖表

Product Code: VMR112112026

The global demand for Lung Disease Therapeutics Market is presumed to reach the market size of nearly USD 116.41 BN by 2030 from USD 80.41 BN in 2022 with a CAGR of 4.7% under the study period 2023 - 2030.

Lung disease therapeutics refers to the medical treatments and interventions aimed at managing and treating various lung-related disorders and diseases. It covers conditions affecting the respiratory system, including both acute and chronic diseases that impact lung function and overall respiratory health. These therapeutics can involve various approaches, including medications, therapies, changes in lifestyle, and, in some cases, surgical interventions.

MARKET DYNAMICS:

The increasing prevalence of lung diseases, driven by factors like pollution and ageing populations, fuels the demand for effective treatments. Environmental factors, technological advancements, and research contribute to the growing need for therapies. Personalized medicine and emerging biopharmaceuticals, such as targeted therapies, enhance treatment options. Rising healthcare expenditure, early diagnosis awareness, and stricter regulatory standards play significant roles. The COVID-19 pandemic highlighted respiratory health's importance and accelerated research in the field. Global initiatives, healthcare infrastructure development, and a patient-centric approach further influence the market. As patients and healthcare professionals seek improved therapies, the market is anticipated to evolve.

The research report covers Porter's Five Forces Model, Market Attractiveness Analysis, and Value Chain analysis. These tools help to get a clear picture of the industry's structure and evaluate the competition attractiveness at a global level. Additionally, these tools also give an inclusive assessment of each segment in the global market of lung disease therapeutics. The growth and trends of lung disease therapeutics industry provide a holistic approach to this study.

MARKET SEGMENTATION:

This section of the lung disease therapeutics market report provides detailed data on the segments at country and regional level, thereby assisting the strategist in identifying the target demographics for the respective product or services with the upcoming opportunities.

By Disease Type

Asthma
Chronic Obstructive Pulmonary Disease (COPD)
Lung Cancer
Other Lung Disease

By Drug Class

Corticosteroids
Bronchodilator Medications
Mucolytics
Antimicrobial Medications
Others

By Distribution Channel

Hospital Pharmacies
Retail Pharmacies
Online Pharmacies

REGIONAL ANALYSIS:

This section covers the regional outlook, which accentuates current and future demand for the Lung Disease Therapeutics market across North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. Further, the report focuses on demand, estimation, and forecast for individual application segments across all the prominent regions.

The research report also covers the comprehensive profiles of the key players in the market and an in-depth view of the competitive landscape worldwide. The major players in the Lung Disease Therapeutics market include GSK, AstraZeneca, Boehringer Ingelheim, Novartis, Mylan, Vertex Pharmaceuticals, F.Hoffam La Roche, Teva Pharmaceuticals, Cipla, Fibrogen, Liminal Biosciences, PharmAkea Therapeutics, IQVIA. This section consists of a holistic view of the competitive landscape that includes various strategic developments such as key mergers & acquisitions, future capacities, partnerships, financial overviews, collaborations, new product developments, new product launches, and other developments.

In case you have any custom requirements, do write to us. Our research team can offer a customized report as per your need.

1 . PREFACE

1.1. Report Description
- 1.1.1. Objective
- 1.1.2. Target Audience
- 1.1.3. Unique Selling Proposition (USP) & offerings
1.2. Research Scope
1.3. Research Methodology
- 1.3.1. Market Research Process
- 1.3.2. Market Research Methodology

2 . EXECUTIVE SUMMARY

2.1. Highlights of Market
2.2. Global Market Snapshot

3 . LUNG DISEASE THERAPEUTICS - INDUSTRY ANALYSIS

3.1. Introduction - Market Dynamics
3.2. Market Drivers
3.3. Market Restraints
3.4. Opportunities
3.5. Industry Trends
3.6. Porter's Five Force Analysis
3.7. Market Attractiveness Analysis
- 3.7.1 Market Attractiveness Analysis By Disease Type
- 3.7.2 Market Attractiveness Analysis By Drug Class
- 3.7.3 Market Attractiveness Analysis By Distribution Channel
- 3.7.4 Market Attractiveness Analysis By Region

4 . VALUE CHAIN ANALYSIS

4.1. Value Chain Analysis
4.2. Raw Material Analysis
- 4.2.1. List of Raw Materials
- 4.2.2. Raw Material Manufactures List
- 4.2.3. Price Trend of Key Raw Materials
4.3. List of Potential Buyers
4.4. Marketing Channel
- 4.4.1. Direct Marketing
- 4.4.2. Indirect Marketing
- 4.4.3. Marketing Channel Development Trend

5 . GLOBAL LUNG DISEASE THERAPEUTICS MARKET ANALYSIS BY DISEASE TYPE

5.1 Overview by Disease Type
5.2 Historical and Forecast Data
5.3 Analysis by Disease Type
5.4 Asthma Historic and Forecast Sales by Regions
5.5 Chronic Obstructive Pulmonary Disease (COPD) Historic and Forecast Sales by Regions
5.6 Lung Cancer Historic and Forecast Sales by Regions
5.7 Other Lung Disease Historic and Forecast Sales by Regions

6 . GLOBAL LUNG DISEASE THERAPEUTICS MARKET ANALYSIS BY DRUG CLASS

6.1 Overview by Drug Class
6.2 Historical and Forecast Data
6.3 Analysis by Drug Class
6.4 Corticosteroids Historic and Forecast Sales by Regions
6.5 Bronchodilator Medications Historic and Forecast Sales by Regions
6.6 Mucolytics Historic and Forecast Sales by Regions
6.7 Antimicrobial Medications Historic and Forecast Sales by Regions
6.8 Others Historic and Forecast Sales by Regions

7 . GLOBAL LUNG DISEASE THERAPEUTICS MARKET ANALYSIS BY DISTRIBUTION CHANNEL

7.1 Overview by Distribution Channel
7.2 Historical and Forecast Data
7.3 Analysis by Distribution Channel
7.4 Hospital Pharmacies Historic and Forecast Sales by Regions
7.5 Retail Pharmacies Historic and Forecast Sales by Regions
7.6 Online Pharmacies Historic and Forecast Sales by Regions

8 . GLOBAL LUNG DISEASE THERAPEUTICS MARKET ANALYSIS BY GEOGRAPHY

8.1. Regional Outlook
8.2. Introduction
8.3. North America Sales Analysis
- 8.3.1. Overview, Historic and Forecast Data Sales Analysis
- 8.3.2. North America By Segment Sales Analysis
- 8.3.3. North America By Country Sales Analysis
- 8.3.4. United State Sales Analysis
- 8.3.5. Canada Sales Analysis
- 8.3.6. Mexico Sales Analysis
8.4. Europe Sales Analysis
- 8.4.1. Overview, Historic and Forecast Data Sales Analysis
- 8.4.2. Europe by Segment Sales Analysis
- 8.4.3. Europe by Country Sales Analysis
- 8.4.4. United Kingdom Sales Analysis
- 8.4.5. France Sales Analysis
- 8.4.6. Germany Sales Analysis
- 8.4.7. Italy Sales Analysis
- 8.4.8. Russia Sales Analysis
- 8.4.9. Rest Of Europe Sales Analysis
8.5. Asia Pacific Sales Analysis
- 8.5.1. Overview, Historic and Forecast Data Sales Analysis
- 8.5.2. Asia Pacific by Segment Sales Analysis
- 8.5.3. Asia Pacific by Country Sales Analysis
- 8.5.4. China Sales Analysis
- 8.5.5. India Sales Analysis
- 8.5.6. Japan Sales Analysis
- 8.5.7. South Korea Sales Analysis
- 8.5.8. Australia Sales Analysis
- 8.5.9. South East Asia Sales Analysis
- 8.5.10. Rest Of Asia Pacific Sales Analysis
8.6. Latin America Sales Analysis
- 8.6.1. Overview, Historic and Forecast Data Sales Analysis
- 8.6.2. Latin America by Segment Sales Analysis
- 8.6.3. Latin America by Country Sales Analysis
- 8.6.4. Brazil Sales Analysis
- 8.6.5. Argentina Sales Analysis
- 8.6.6. Peru Sales Analysis
- 8.6.7. Chile Sales Analysis
- 8.6.8. Rest of Latin America Sales Analysis
8.7. Middle East & Africa Sales Analysis
- 8.7.1. Overview, Historic and Forecast Data Sales Analysis
- 8.7.2. Middle East & Africa by Segment Sales Analysis
- 8.7.3. Middle East & Africa by Country Sales Analysis
- 8.7.4. Saudi Arabia Sales Analysis
- 8.7.5. UAE Sales Analysis
- 8.7.6. Israel Sales Analysis
- 8.7.7. South Africa Sales Analysis
- 8.7.8. Rest Of Middle East And Africa Sales Analysis

9 . COMPETITIVE LANDSCAPE OF THE LUNG DISEASE THERAPEUTICS COMPANIES

9.1. Lung Disease Therapeutics Market Competition
9.2. Partnership/Collaboration/Agreement
9.3. Merger And Acquisitions
9.4. New Product Launch
9.5. Other Developments

10 . COMPANY PROFILES OF LUNG DISEASE THERAPEUTICS INDUSTRY

10.1. Company Share Analysis
10.2. Market Concentration Rate
10.3. GSK
- 10.3.1. Company Overview
- 10.3.2. Company Revenue
- 10.3.3. Products
- 10.3.4. Recent Developments
10.4. AstraZeneca
- 10.4.1. Company Overview
- 10.4.2. Company Revenue
- 10.4.3. Products
- 10.4.4. Recent Developments
10.5. Boehringer Ingelheim
- 10.5.1. Company Overview
- 10.5.2. Company Revenue
- 10.5.3. Products
- 10.5.4. Recent Developments
10.6. Novartis
- 10.6.1. Company Overview
- 10.6.2. Company Revenue
- 10.6.3. Products
- 10.6.4. Recent Developments
10.7. Mylan
- 10.7.1. Company Overview
- 10.7.2. Company Revenue
- 10.7.3. Products
- 10.7.4. Recent Developments
10.8. Vertex Pharmaceuticals
- 10.8.1. Company Overview
- 10.8.2. Company Revenue
- 10.8.3. Products
- 10.8.4. Recent Developments
10.9. F.Hoffam La Roche
- 10.9.1. Company Overview
- 10.9.2. Company Revenue
- 10.9.3. Products
- 10.9.4. Recent Developments
10.10. Teva Pharmaceuticals
- 10.10.1. Company Overview
- 10.10.2. Company Revenue
- 10.10.3. Products
- 10.10.4. Recent Developments
10.11. Cipla
- 10.11.1. Company Overview
- 10.11.2. Company Revenue
- 10.11.3. Products
- 10.11.4. Recent Developments
10.12. Fibrogen
- 10.12.1. Company Overview
- 10.12.2. Company Revenue
- 10.12.3. Products
- 10.12.4. Recent Developments
10.13. Liminal Biosciences
- 10.13.1. Company Overview
- 10.13.2. Company Revenue
- 10.13.3. Products
- 10.13.4. Recent Developments
10.14. PharmAkea Therapeutics
- 10.14.1. Company Overview
- 10.14.2. Company Revenue
- 10.14.3. Products
- 10.14.4. Recent Developments
10.15. IQVIA
- 10.15.1. Company Overview
- 10.15.2. Company Revenue
- 10.15.3. Products
- 10.15.4. Recent Developments